Equity · Healthcare
Iovance Biotherapeutics, Inc. (IOVA) perpetual futures
Iovance Biotherapeutics is a clinical-stage biotechnology company developing cancer immunotherapies that use a patient's own immune system, including lifileucel for advanced melanoma and LN-145 for head and neck cancer.
Price chart
Interactive TradingView chart
TradingView symbol NASDAQ:IOVA
Loads TradingView's third-party widget (about 1 MB) on demand.
Trading data
Perpetual market activity
0/1 live markets
Trading data
Perpetual market activity
Spot performance
Best venues for this underlying
Best liquidity
-Tightest spread
-Highest volume
-Next catalyst
Catalysts
Next catalyst
Catalysts
No unusual perp activity right now.
Research data
Analysts, filings and peer context
Research data
Analysts, filings and peer context
Estimates
6Company events
6Peer comparison
Similar listed perpsRevenue mix
Latest annualAnalysts
Price targets in USD| Consensus rating | Buy |
|---|---|
| Average 12-month price target | $13.56 |
| 12-month target range (low – high) | $5 – $20 |
| Ratings in the provider's consensus | 21 |
Price targets as of 2026-11-21
Analyst rating history
Ratings| Month | Strong buy | Buy | Hold | Sell | Strong sell |
|---|---|---|---|---|---|
| Nov 2026 | 2 | 5 | 2 | 0 | 0 |
| Oct 2026 | 2 | 6 | 2 | 0 | 0 |
| Sep 2026 | 2 | 6 | 2 | 0 | 0 |
| Aug 2026 | 2 | 5 | 2 | 0 | 0 |
| Jul 2026 | 2 | 6 | 2 | 0 | 0 |
| Jun 2026 | 2 | 6 | 2 | 0 | 0 |
| May 2026 | 2 | 6 | 3 | 0 | 0 |
| Apr 2026 | 2 | 6 | 3 | 0 | 0 |
| Mar 2026 | 2 | 6 | 3 | 0 | 0 |
| Feb 2026 | 2 | 6 | 4 | 1 | 0 |
| Jan 2026 | 1 | 6 | 4 | 1 | 0 |
| Dec 2025 | 1 | 6 | 4 | 1 | 0 |
Ownership
Institutional · 2026-Q3Reference market activity
IOVA-PERPPrice performance
11Insider activity
FY2026 Q4Insider transactions
25Director and Interim CEO Frederick Vogt exercised 200,000 stock options at $7.55 into common stock, then had 191,303 shares withheld for taxes at $8.09. He held 604,144 shares after.
Iovance officer Kirby Daniel Gordon exercised 10,000 restricted stock units into common stock, then 3,935 shares were withheld for taxes at $8.08, leaving 160,576 shares owned.
Iovance CFO Roche Corleen M. converted 12,500 restricted stock units into 12,500 common shares on Nov 6, 2026, then had 5,311 shares withheld for taxes at $8.04. She held 35,946 common shares afterward.
Iovance CMO Noah Berkowitz received three awards on 2026-09-30: 180,000 restricted stock units, 135,000 performance stock units, and 135,000 stock options at $14.82. All are grants, not open-market purchases.
Iovance Biotherapeutics officer Noah Berkowitz filed a Form 3 on 2026-10-02, an initial statement of beneficial ownership reporting 0 shares of common stock as of 2026-09-30.
Director Vogt exercised 15,626 restricted stock units into 15,626 common shares, with 6,638 shares withheld at $8.70 for taxes; he held 595,447 shares after.
Iovance officer Igor Bilinsky converted 7,813 restricted stock units into 7,813 common shares, then 3,976 shares were withheld at $8.70 for taxes, leaving 142,074 shares owned.
Iovance officer Raj K. Puri converted 9,766 restricted stock units into 9,766 common shares, and 4,478 shares were withheld for taxes at $8.70, leaving 256,364 shares owned.
Vesting of RSUs converted 41,669 restricted stock units into common stock; 17,702 shares were withheld for taxes at $8.28 each.
Filings
48 · Latest SEC filingsDirector and Interim CEO Frederick Vogt exercised 200,000 stock options at $7.55 into common stock, then had 191,303 shares withheld for taxes at $8.09. He held 604,144 shares after.
Iovance officer Kirby Daniel Gordon exercised 10,000 restricted stock units into common stock, then 3,935 shares were withheld for taxes at $8.08, leaving 160,576 shares owned.
Iovance CFO Roche Corleen M. converted 12,500 restricted stock units into 12,500 common shares on Nov 6, 2026, then had 5,311 shares withheld for taxes at $8.04. She held 35,946 common shares afterward.
Iovance Biotherapeutics officer Noah Berkowitz filed a Form 3 on 2026-10-02, an initial statement of beneficial ownership reporting 0 shares of common stock as of 2026-09-30.
Iovance CMO Noah Berkowitz received three awards on 2026-09-30: 180,000 restricted stock units, 135,000 performance stock units, and 135,000 stock options at $14.82. All are grants, not open-market purchases.
Director Vogt exercised 15,626 restricted stock units into 15,626 common shares, with 6,638 shares withheld at $8.70 for taxes; he held 595,447 shares after.
Iovance officer Igor Bilinsky converted 7,813 restricted stock units into 7,813 common shares, then 3,976 shares were withheld at $8.70 for taxes, leaving 142,074 shares owned.
Iovance officer Raj K. Puri converted 9,766 restricted stock units into 9,766 common shares, and 4,478 shares were withheld for taxes at $8.70, leaving 256,364 shares owned.
Chief Regulatory Officer Puri Raj K. converted 5,470 restricted stock units into common shares; 2,508 shares were withheld to cover taxes at $8.28.
Igor Bilinsky, COO of Iovance Biotherapeutics, converted 8,789 RSUs into common stock and disposed of 4,472 shares for tax withholding.
Vesting of RSUs converted 41,669 restricted stock units into common stock; 17,702 shares were withheld for taxes at $8.28 each.
Daniel Kirby, CCO of IOVA, converted 10,001 RSUs into common stock, with 2,436 shares withheld for taxes (at $6.40), leaving 154,511 shares owned.
Chief Financial Officer converted 49,995 RSUs into common stock and had 21,238 shares withheld to cover taxes.
Chief Regulatory Officer Puri Raj K. received a grant of 15,000 restricted stock units (RSUs) from Iovance Biotherapeutics.
Director Dukes Iain D. received a grant of 180,632 deferred restricted stock units (Award) at $0.00 per share, with no purchase or sale involved.
Director Michael Weiser received a grant of 90,316 deferred restricted stock units with no exercise price.
Director Athena Countouriotis received an award of 90,316 deferred restricted stock units on 2026-06-16, reported on a Form 4 filed 2026-06-18.
Director Maynard Ryan D received an award of 90,316 deferred restricted stock units from Iovance Biotherapeutics, as reported in a Form 4 filing.
Director/CEO exercised 15,625 RSUs, converting them into common stock, with 6,638 shares withheld for taxes.
Puri Raj K. converted 9,766 RSUs into common shares; 3,843 shares were withheld to cover taxes.
On June 5, 2026, the reporting person converted 7,813 RSUs into common stock, with 3,976 shares withheld for taxes at $4.23, leaving 133,920 shares owned.
Iovance officer Friedrich Graf Finckenstein reported an RSU conversion: 7,813 restricted stock units converted into 7,813 common shares, with 3,976 shares withheld for taxes at $4.23. He holds 140,111 shares after these transactions.
Igor Bilinsky (COO of Iovance Biotherapeutics) converted 8,790 RSUs into 8,790 common shares, with 4,473 shares withheld for taxes.
Chief Medical Officer Friedrich Graf Finckenstein converted 8,790 RSUs into common stock, with 4,473 shares withheld for taxes.
IOVA officer Frederick Vogt converted 41,668 restricted stock units into 41,668 common shares and had 17,701 shares withheld for taxes at $3.96, leaving 553,505 shares.
Puri Raj K., Chief Regulatory Officer of Iovance Biotherapeutics, converted 5,469 RSUs into 5,469 common shares; 2,508 shares were withheld for taxes at $3.96 each.
Officer converted 10,000 RSUs into 10,000 common shares; 2,435 shares withheld for taxes at $3.70.
Transcripts
PendingCompany news
Reuters, WSJ, Bloomberg and FT first, as far as our news provider delivers them; other publishers behind the second filter. Headlines link to the publisher.No articles from Reuters, WSJ, Bloomberg or FT for this company in our feed.
Company data
Company intelligence
Updated: Nov 21, 2026, 07:58 PM UTC
Company data
Company intelligence
Company profile
- Sector
- Healthcare
- Industry
- Biotechnology
- Chief executive
- Frederick G. Vogt
- Employees
- 975
- IPO date
- Oct 15, 2010
- Country
- US
- Exchange
- NASDAQ Global Market
Rating factors
- Return on equityi
- 1/5
- Return on assetsi
- 1/5
- Debt to equityi
- 4/5
- Price to earningsi
- 1/5
- Price to booki
- 3/5
Company press releases
Market cap history
Largest fund holders
| Fund | Weight | Shares held |
|---|---|---|
| VTI | 0.01% | 13.5M |
| XBI | 1.04% | 12.1M |
| IWM | 0.11% | 10.1M |
| NJM | 0.04% | 7.9M |
| VB | 0.04% | 4.8M |
| VXF | 0.07% | 4.4M |
| FSSNX | 0.1% | 4.2M |
| IWN | 0.23% | 3.7M |
| FSMAX | 0.07% | 3.2M |
| IBB | 0.23% | 3.1M |
| NAJ | 0.08% | 2.9M |
| VTWO | 0.19% | 2.3M |
Analyst track record
How the analysts covering IOVA have done: ratings, price-target accuracy and the measured reaction after their calls.
| 12 months | 3 years | |
|---|---|---|
| Ratings | 60 | 220 |
| Analysts | 14 | 23 |
| Buy / hold / sell | 49 / 10 / 1 | 192 / 25 / 3 |
| Upgrades / downgrades / initiations | 1 / 0 / 1 | 1 / 6 / 2 |
| Price targets hit / missed | 10 / 47 (18%) | 29 / 167 (15%) |
| Avg. return after a rating (TipRanks) | -21.7% | -33.1% |
| Best / worst call | +265.5% / -63.5% | +631.0% / -78.5% |
After buy calls on this stock: median 21-day move -4.6% vs S&P 500 -8.6% (n = 209)
Most accurate on this stock
Share of an analyst's price targets on this stock that the price reached within 12 months (our measurement over the last 3 years, at least 8 targets). It describes past calls, not the odds of the current one.
- Yanan ZhuWells Fargo17% hit rate on this stock · 18 targets measuredBuytarget $18.00Oct 29, 2026
- Joseph PantginisH.C. Wainwright14% hit rate on this stock · 21 targets measuredBuytarget $20.00Nov 11, 2026
- Colleen M. KusyRobert W. Baird0% hit rate on this stock · 10 targets measuredHoldtarget $9.00Oct 30, 2026
Latest ratings
| Date | Analyst | Call | Target | |
|---|---|---|---|---|
| Nov 20, 2026 | Salim SyedMizuho SecuritiesNov 20, 2026 | HoldDowngraded | $7.00↗ | article ↗ |
| Nov 11, 2026 | Joseph PantginisH.C. WainwrightNov 11, 2026 | BuyReiterated | $20.00↗ | article ↗ |
| Nov 6, 2026 | Reni BenjaminCitizens JMPNov 6, 2026 | BuyMaintained | $12.00↗ | article ↗ |
| Nov 6, 2026 | Etzer DaroutBarclaysNov 6, 2026 | BuyMaintained | $19.00↗ | article ↗ |
| Nov 5, 2026 | Joseph PantginisH.C. WainwrightNov 5, 2026 | BuyReiterated | $20.00↗ | article ↗ |
Share of analysts per call each month (latest call per analyst within 180 days). Targets and closes in USD.
TipRanks data · computed Nov 21, 2026 · 60 ratings
BingX